The COVID-19 pandemic: progress in nephrology

Patients with kidney disease are particularly vulnerable to COVID-19. In 2021, key studies demonstrated the safety of renin–angiotensin blockade in patients with kidney failure and COVID-19, and provided new data on the therapeutic potential of soluble angiotensin-converting enzyme, COVID-19 vaccine...

Descripción completa

Detalles Bibliográficos
Autores principales: Soler, María José, Jacobs-Cachá, Conxita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Year in Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8646337/
https://www.ncbi.nlm.nih.gov/pubmed/34873314
http://dx.doi.org/10.1038/s41581-021-00521-4
Descripción
Sumario:Patients with kidney disease are particularly vulnerable to COVID-19. In 2021, key studies demonstrated the safety of renin–angiotensin blockade in patients with kidney failure and COVID-19, and provided new data on the therapeutic potential of soluble angiotensin-converting enzyme, COVID-19 vaccine responses and the long-term effects of COVID-19 on kidney function.

Ejemplares similares